hit counter
Bellerophon Therapeutics, Inc. (BLPH) Stock News Sentiment & Price - Sentifly
BLPH - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Bellerophon Therapeutics, Inc. (BLPH)

USA
Biotechnology
NASDAQ
BLPH Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
BLPH Latest news
GlobeNewsWire
Neutral
Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
2021-09-07 08:30

WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 13-15, 2021.

Benzinga
Neutral
Why Entera Bio, Orphazyme, Bellerophon Are Moving Today
2021-06-23 13:22

Entera Bio Ltd. (NASDAQ: ENTX), Orphazyme A/S (NASDAQ: ORPH) and Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) are among the biggest biopharma movers Wednesday.

PennyStocks
Positive
8 Hot Biotech Penny Stocks For Your July 2021 Watch List
2021-06-23 11:27

Current & Former Penny Stocks To Watch Before July The post 8 Hot Biotech Penny Stocks For Your July 2021 Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

GlobeNewsWire
Neutral
Bellerophon to Present at the Jefferies Virtual Healthcare Conference
2021-05-27 08:30

WARREN, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the Jefferies Virtual Healthcare Conference, being held June 1-4, 2021.

GlobeNewsWire
Neutral
Bellerophon Appoints Naseem Amin, M.D. as Chairman of its Board of Directors
2021-05-26 08:30

Dr. Amin Has Served as an Independent Director Since 2015 and Succeeds Jonathan Peacock Following Mr. Peacock's Retirement from the Company's Board Dr. Amin Has Served as an Independent Director Since 2015 and Succeeds Jonathan Peacock Following Mr. Peacock's Retirement from the Company's Board

GlobeNewsWire
Neutral
Bellerophon Provides Clinical Program Update and Reports First Quarter 2021 Financial Results
2021-05-11 08:30

WARREN, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2021.

GlobeNewsWire
Neutral
Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
2021-03-11 08:30

WARREN, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the fourth quarter and year ended December 31, 2020.

GlobeNewsWire
Neutral
Bellerophon to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
2021-01-04 08:30

WARREN, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021.

GlobeNewsWire
Neutral
Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease
2020-12-01 08:30

WARREN, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the first patient has been enrolled in its REBUILD Phase 3 registrational clinical study evaluating INOpulse®, a pulsed inhaled nitric oxide therapy, as a potential treatment for fibrotic interstitial lung disease (fILD).

Insider Monkey
Negative
Here is What Hedge Funds Think About Bellerophon Therapeutics, Inc. (BLPH)
2020-11-28 20:49

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an individual investor's stock selection process, as it may offer great insights of how the brightest minds of the finance industry feel about specific stocks. After all, these people have access to smartest analysts and expensive data/information sources that individual investors can't match. So should one consider investing in Bellerophon Therapeutics, Inc. (NASDAQ:BLPH)? The smart money sentiment can provide an answer to this question.

Loading more news...